Three completed cohorts reporting findings in non-small cell lung cancer, breast, and metastatic colorectal cancer from the American Society of Clinical Oncology Inc.'s Targeted Agent and Profiling Utilization Registry study were presented in poster sessions during the American Association for Cancer Research Annual Meeting 2019.
FDA announced steps to modernize breast cancer screening and help empower patients with more information when they are considering important decisions regarding their breast health care.
FDA is alerting health care professionals, oncology clinical investigators and patients about the risks associated with the investigational use of Venclexta (venetoclax) for the treatment of patients with multiple myeloma based on data from a clinical trial. Venclexta is not approved for the treatment of multiple myeloma.
The Janssen Pharmaceutical Co. has submitted a supplemental Biologics License Application to FDA seeking approval of Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant.
Breath Diagnostics Inc. and Mayo Clinic Laboratories announced a collaboration to develop clinical diagnostic tests that use patient breath samples to identify individual biomarkers that can predict a spectrum of diseases. The two organizations will initially focus on a test that can detect lung cancer.
Oncoceutics Inc., has partnered with NIH with matters related to its imipridone family of anti-cancer compounds. ONC206 has been studied extensively for several years in models of central nervous system cancers, including high grade gliomas as evaluated by the laboratory of Mark Gilbert, chief of the Neuro-Oncology Branch, Center for Cancer Research, NCI.
Elicio Therapeutics announced the appointment of Robert Connelly as CEO. Elicio is developing precision vaccines, immuno-stimulators, and cellular therapies based on the work of Darrell Irvine, professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
FDA approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide, for the initial treatment of adults with extensive-stage small cell lung cancer.
Strata Oncology announced the launch of version 3.0 of StrataNGS, its pan-cancer assay for solid tumors.
Oncoceutics Inc., announces the expansion of its diverse collaborations across the NIH involving its imipridone family of anti-cancer compounds.
